IL6 and COVID-19: The efficacy of sarilumab in COVID-19 is controversial: some RCTs show better outcomes with early IL-6 blockade through a single dose of sarilumab (Merchante et al., 2022), while others have failed to show significant improvements in clinical status or mortality (Sivapalasingam et al., 2022).